| Abstract: |
Clinical strategies which modulate the human anti-mouse antibody response (HAMA) in patients may have a profound influence on the idiotype network inducible by murine monoclonal antibodies (MoAb). Prior to myeloablative chemotherapy (ABMT), 9 patients with Stage IV neuroblastoma were imaged with 131I-3F8, a MoAb specific for the ganglioside GD2. Their serum HAMA, anti-idiotypic, anti-GD2, and anti-anti-idiotypic antibodies were assayed by enzyme-linked immunosorbent assay prior to, and at 3 and 6 months postimaging. HAMA and anti-idiotypic levels remained low, in contrast to the high levels in 10 patients imaged with 131I-3F8 Iro without ABMT. Five of the 9 patients are long-term survivors; all had elevated anti-GD2 and anti-anti-idiotypic levels, significantly higher than those who died of disease. Although 131I-3F8 imaging prior to ABMT detected abnormal sites in 4 of 9 patients, 3 of the 4 patients have continued in remission for 24–63 months after ABMT, and all 3 mounted anti-GD2 and anti-anti-idiotypic antibody responses. We conclude that myeloablative therapy strongly suppressed the HAMA/anti-idiotypic response to murine MoAb and that the prognostic significance of host immune response to ganglioside GD2 MoAb deserves further investigation. © 1994, American Association for Cancer Research. All rights reserved. |
| Keywords: |
cancer survival; clinical article; controlled study; survival analysis; survival rate; cisplatin; neoplasm staging; animal; mice; bone marrow suppression; etoposide; antineoplastic combined chemotherapy protocols; radiotherapy dosage; melphalan; carmustine; thiotepa; monoclonal antibody; antibodies, monoclonal; neuroblastoma; antibody response; immunoassay; enzyme-linked immunosorbent assay; bone marrow transplantation; antibody formation; gangliosides; ganglioside antibody; antibodies, anti-idiotypic; antibody blood level; prognosis; human; priority journal; article; support, non-u.s. gov't; support, u.s. gov't, p.h.s.
|
